I have type 2 diabetes. Can I use the Medicare GLP-1 Bridge?

No. Type 2 diabetes already qualifies you for GLP-1 coverage through your regular Part D plan, so people with type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH are excluded from the Bridge. The Bridge exists for people seeking a GLP-1 for weight itself who have no covered path today.

Does the $50 copay count toward my Part D deductible or the $2,100 drug spending cap?

No. The Bridge runs outside the normal Part D benefit, so the $50 copays don't count toward your deductible or the annual out-of-pocket cap, and Extra Help subsidies don't lower the copay.

How do I sign up for the Medicare GLP-1 Bridge?

There is no signup for beneficiaries. Your doctor submits the prescription and a prior authorization request to the program, which targets decisions within 72 hours. After the first approved fill, refills don't need new authorization unless you switch to a different covered medication.

Do I still qualify if my BMI has dropped since starting a GLP-1?

Yes, if you met the BMI criteria when GLP-1 therapy began. The thresholds apply at the time treatment starts, and your doctor attests that you met them at initiation even if the medication has since lowered your BMI.

What happens when the Medicare GLP-1 Bridge ends in December 2027?

That hasn't been decided. CMS is collecting data from the Bridge program to inform a possible longer-term Medicare coverage program for GLP-1s, but no permanent coverage has been finalized, so discuss that uncertainty with your doctor before starting.

Medicare Now Covers GLP-1s for Weight Loss: Who Qualifies for the New $50 Bridge Program

July 1, 2026

Dr. Damian Rasch, D.O.

Medically Reviewed & Edited

Board-Certified Invasive Cardiologist
Encinitas and La Jolla, CA

Developed with digital research and writing assistance, then medically reviewed and edited by Dr. Rasch to ensure clinical accuracy and adherence to current evidence-based guidelines.

Last reviewed and updated on July 1, 2026

For the past two years, one of the most common questions in my clinic has come from patients on Medicare. Can I get Wegovy or Zepbound covered? Until today, my answer was usually no. Medicare drug plans were barred by law from paying for weight loss medications, so unless you had type 2 diabetes or one of a few other specific diagnoses, the sticker price was yours to carry, often more than $1,000 a month. Plenty of my patients who stood to gain the most from these medications simply could not afford them.

Today, July 1, 2026, that changes. A new federal pilot called the Medicare GLP-1 Bridge starts covering three GLP-1 medications for weight loss at a copay of $50 a month. It runs through December 31, 2027, and by one estimate from KFF, nearly 3.8 million people on Medicare could qualify. The rules take some untangling, so let me walk you through them the way I would in the office.

What actually changed

The Medicare GLP-1 Bridge is a short-term demonstration run by the Centers for Medicare and Medicaid Services (CMS). It is the first time Medicare has paid for GLP-1 drugs prescribed purely to reduce excess body weight or keep it off. Before today, Medicare covered these medications only when they were prescribed for something else. Ozempic and Mounjaro for type 2 diabetes. Wegovy to lower the risk of heart attack and stroke in people with established heart disease. Zepbound for moderate to severe sleep apnea. Weight loss on its own didn’t count.

The Bridge opens a separate door. If you meet the medical criteria below and you’re enrolled in a Medicare drug plan, your doctor can now get you one of the covered medications for a $50 copay on each 30-day supply.

Who qualifies

You must be at least 18 and enrolled in a Medicare drug plan, either a standalone Part D plan or a Medicare Advantage plan that includes drug coverage. CMS says most people with Part D are in eligible plans, so you likely don’t need to switch anything.

The medical criteria are based on your body mass index (BMI) at the time you start treatment, plus your other diagnoses. BMI is a rough measure of weight relative to height; a BMI of 30 or higher counts as obesity. You qualify if you fall into any one of these three groups:

BMI of 35 or higher. Nothing else required.
BMI of 30 or higher plus at least one of the following: heart failure with preserved ejection fraction (HFpEF, the kind where the heart pumps normally but is too stiff to fill properly), high blood pressure that stays above 140 systolic or 90 diastolic despite treatment with two blood pressure medications, or chronic kidney disease at stage 3a or above (moderately reduced kidney function).
BMI of 27 or higher plus at least one of the following: prediabetes, a previous heart attack, a previous stroke, or peripheral artery disease with symptoms, the leg pain or cramping that comes from narrowed arteries in the legs.

One detail worth knowing. The BMI test applies at the time you start GLP-1 therapy. If you started at a BMI of 36 and the medication has already brought you down to 33, your doctor attests that you met the threshold when treatment began. Losing weight on the drug doesn’t disqualify you from staying on it.

Who this program is not for

Here’s the part that confuses people. If you have type 2 diabetes, moderate to severe obstructive sleep apnea, or the liver condition called MASH, you are not eligible for the Bridge, even if your BMI qualifies. That sounds like a snub. It isn’t. Those diagnoses already qualify you for GLP-1 coverage through your regular Part D plan, and CMS wants you to use that route instead. The same goes for people prescribed Wegovy to protect against heart attack and stroke after a cardiac event; that use runs through your plan’s normal coverage.

So the Bridge is aimed at one group in particular, people who want a GLP-1 for weight itself and until now had no covered path to get one.

Which drugs are covered, and what you’ll pay

Three medications are on the list: Wegovy in all its forms (the weekly injection and the newer tablet), Foundayo tablets, and Zepbound in its KwikPen form only. Ozempic and Mounjaro are not included, since those are the diabetes-labeled versions of the same molecules.

The copay is $50 for each 30-day supply. A few catches come with that number. The $50 doesn’t count toward your Part D deductible or toward the $2,100 annual out-of-pocket cap on drug costs. If you get Extra Help with your drug costs, that subsidy doesn’t apply here either, so the copay is $50 for everyone. And you can’t spread it out through the Medicare Prescription Payment Plan. Still, for medications that have been running four figures a month out of pocket, $50 is a different world.

How you actually get it

There’s no enrollment form and nothing to sign up for on your end. The process runs through your doctor.

Your doctor submits a prescription along with a prior authorization request to the Bridge program, and attests that the medication is being prescribed to reduce excess weight and keep it off, combined with lifestyle changes like diet and exercise. CMS has committed to a 72-hour turnaround on those decisions, so expect the first fill to take a few days rather than an afternoon. After that first approved fill, refills don’t need a new authorization unless you switch to a different covered drug.

One quirk to remember. Your Part D plan is not part of this program. An outside processor handles the claims centrally, so if something goes wrong, calling your plan will get you nowhere. Questions and problems go to 1-800-MEDICARE (1-800-633-4227), and the program details live at Medicare.gov.

Why this matters to me as a cardiologist

Read that eligibility list again and you’ll notice something. It’s a list of my patients. Stiff-heart failure, prior heart attacks and strokes, blood pressure that won’t budge on two medications, peripheral artery disease, kidney disease. These are cardiovascular conditions, and CMS built the program around them because excess weight feeds every one of them.

The evidence behind these medications is strong. In the trials, people taking semaglutide (the drug in Wegovy) lost an average of about 15 percent of their body weight, and those on tirzepatide (the drug in Zepbound) lost 18 to 20 percent. For the conditions on the eligibility list, that kind of weight loss translates into lower blood pressure, better blood sugar, less strain on a stiff heart, and slower kidney decline. I’ve written a full guide to how GLP-1 medications work, what to expect, and their side effects, and everything in it applies here.

I’ll add two honest cautions. First, this is a pilot with an end date. It runs through December 2027, and nobody can promise what coverage looks like after that. CMS has said it will use the data to shape a possible permanent program, but if you start one of these medications, go in knowing the coverage question may reopen in 18 months. Stopping a GLP-1 usually means some of the weight comes back, so that uncertainty belongs in the conversation with your doctor from day one.

Second, a covered prescription is a tool, and it works best inside a real plan. The program itself requires your doctor to pair the medication with diet and exercise, and that requirement reflects how these drugs actually succeed. Weight loss and exercise move blood pressure and heart risk on their own, and the medication amplifies that work rather than replacing it.

If you want a deeper consumer-level look at the program, AARP published an excellent walkthrough this week that covers the mechanics in detail: Medicare’s $50-a-Dose GLP-1 Benefit for Weight Loss Is Here.

Frequently Asked Questions

Is Ozempic covered under the new program?

No. The Bridge covers Wegovy (injection and tablets), Foundayo tablets, and the KwikPen form of Zepbound. Ozempic and Mounjaro are the diabetes-labeled versions and stay under regular Part D coverage for people with type 2 diabetes.

I have type 2 diabetes. Can I use the Bridge?

No, and you don’t need it. Type 2 diabetes already qualifies you for GLP-1 coverage through your regular Part D plan. The Bridge exists for people who have no covered path today, meaning those seeking the medication for weight itself.

Does the $50 copay count toward my deductible or the $2,100 drug spending cap?

No. The Bridge runs outside the normal Part D benefit, so the copays don’t touch your deductible or the annual out-of-pocket cap, and Extra Help subsidies don’t lower the $50.

How do I sign up?

You don’t. Your doctor submits the prescription and a prior authorization request to the program. Decisions are targeted within 72 hours, and after your first approved fill, refills don’t need new paperwork unless you change medications.

My weight dropped since I started a GLP-1 I’ve been paying for out of pocket. Do I still qualify?

The BMI criteria apply at the time you started GLP-1 therapy. If you met a threshold when treatment began, your doctor attests to that, even if the medication has since brought your BMI below it.

What happens when the program ends in December 2027?

Nobody knows yet. CMS is collecting data from the Bridge to inform a possible longer-term Medicare program, but no permanent coverage has been finalized. Build that uncertainty into your plan with your doctor.

References

Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. Accessed July 1, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: Information for Providers. Accessed July 1, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
Centers for Medicare & Medicaid Services. Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries. CMS Newsroom press release. https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries
Medicare.gov. Weight loss drugs. Accessed July 1, 2026. https://www.medicare.gov/coverage/weight-loss-drugs
Pugh T. Medicare’s $50-a-Dose GLP-1 Benefit for Weight Loss Is Here. AARP. June 29, 2026. https://www.aarp.org/medicare/glp1-weight-loss-copay-program/
KFF. Nearly Four Million Medicare Beneficiaries Could Be Eligible for the Temporary Medicare GLP-1 Bridge Program Covering These Drugs for Weight Loss. June 2026. https://www.kff.org/medicare/nearly-four-million-medicare-beneficiaries-could-be-eligible-for-the-temporary-medicare-glp-1-bridge-program-covering-these-drugs-for-weight-loss/
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.